Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities (Q34453538)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities |
scientific article |
Statements
1 reference
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities (English)
1 reference
Wolfgang Koenig
1 reference
Paul M Ridker
1 reference
22 October 2010
1 reference
1 reference
32
1 reference
1
1 reference
75-83
1 reference
Identifiers
1 reference
1 reference
1 reference